Sana Biotechnology reported a cash position of $153.1 million as of the third quarter of 2025, with a pro forma cash balance of $170.5 million including recent at-the-market offering activity. The company raised $115.8 million in aggregate gross proceeds from sales of common stock in the third quarter of 2025. Non-cash expenses related to research and development success payments and contingent consideration totaled $3.1 million for the quarter and $15.3 million for the nine months ended September 30, 2025. Sana recorded a non-cash impairment of long-lived assets of $44.6 million for the nine-month period, primarily related to its manufacturing facility in Bothell, Washington, and certain laboratory and office space in Seattle, Washington. The company has suspended internal investment in allogeneic CAR T studies and further build-out of internal manufacturing capabilities, shifting focus to SC451 for type 1 diabetes and SG293 for in vivo CAR T programs. Sana expects its cash runway to extend into late 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sana Biotechnology Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.
Comments